Co-Authors
This is a "connection" page, showing publications co-authored by Issam Awad and Sean Polster.
Connection Strength
5.885
-
In Reply: Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery. 2021 09 15; 89(4):E247-E248.
Score: 0.797
-
In Reply: Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery. 2020 04 01; 86(4):E411.
Score: 0.721
-
Cavernous angiomas: deconstructing a neurosurgical disease. J Neurosurg. 2019 07 01; 131(1):1-13.
Score: 0.684
-
Patients with cranial dural arteriovenous fistulas may benefit from expanded hypercoagulability and cancer screening. J Neurosurg. 2018 10; 129(4):954-960.
Score: 0.612
-
Intracerebral Hemorrhage: Keep It Simple. Stroke. 2024 Dec; 55(12):2942-2945.
Score: 0.248
-
Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis. J Stroke Cerebrovasc Dis. 2024 Jul; 33(7):107699.
Score: 0.238
-
Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned. J Stroke Cerebrovasc Dis. 2021 Sep; 30(9):105996.
Score: 0.197
-
Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery. 2021 04 15; 88(5):961-970.
Score: 0.194
-
Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials. Oper Neurosurg (Hagerstown). 2020 12 15; 20(1):98-108.
Score: 0.189
-
Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
Score: 0.183
-
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. 2020 05 27; 11(1):2659.
Score: 0.182
-
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
Score: 0.176
-
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery. 2019 06 01; 84(6):1157-1168.
Score: 0.170
-
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
Score: 0.168
-
Combined petrosal approach. Curr Opin Otolaryngol Head Neck Surg. 2018 Oct; 26(5):293-301.
Score: 0.162
-
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
Score: 0.150
-
Fourth-generation Pipeline™ Vantage flow diversion: First reported US experience of safety and feasibility. Interv Neuroradiol. 2024 Dec 05; 15910199241301119.
Score: 0.062
-
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Commun Med (Lond). 2023 Mar 03; 3(1):35.
Score: 0.055
-
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circ Res. 2022 04 15; 130(8):1204-1229.
Score: 0.052
-
Cerebrovascular Complications in Early Survivors of Civilian Penetrating Brain Injury. Neurocrit Care. 2021 06; 34(3):918-926.
Score: 0.047
-
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
Score: 0.047
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
Score: 0.045
-
Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
Score: 0.044
-
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
Score: 0.044
-
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
Score: 0.044
-
Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites. J Magn Reson Imaging. 2020 04; 51(4):1192-1199.
Score: 0.043
-
Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
Score: 0.043
-
Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight. 2019 06 20; 4(12).
Score: 0.043
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
Score: 0.042
-
Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight. 2019 Feb 07; 4(3).
Score: 0.042
-
Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
Score: 0.041
-
The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB J. 2019 02; 33(2):2132-2143.
Score: 0.041
-
Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
Score: 0.040
-
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
Score: 0.039